drugset / Trial / NCT03448939

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03448939

Phase 3 Completed 361 enrolled Sol-Gel Technologies, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

Timeline

Start
2018-06-18
Primary completion
2019-05-24
Completion
2019-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Benzoyl Peroxide Other / unclassified 5 % Topical

Indications